This review highlights how ctDNA helps monitor tumor response in non-small cell lung cancer, suggesting improved clinical outcomes.
Circulating tumour DNA (ctDNA) offers a minimally invasive approach for early detection of cancer, monitoring molecular residual disease, assessing molecular response and identifying treatment resistance in advanced stages. Additionally, ctDNA enhances clinical decision-making by enabling real-time tumour assessment. This review highlights the growing role of liquid biopsy as a predictive and prognostic tool in non-small cell lung cancer management.
No takes yet. Share an insight, caveat, or question.
Jiménez-Munárriz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: